文献速递免疫规划慢病防控与筛查

靶向SOD1疾病特异性表位的肌萎缩侧索硬化治疗性疫苗

Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1.
PubMed 文献 · Vaccine · 2019-07-16

该研究基于突变SOD1错误折叠具有播种和朊病毒样传播的假说,在表达人SOD1-G37R的运动神经元病小鼠模型中评估两种靶向疾病特异性表位的疫苗tgG-DSE2lim和tgG-DSE5b的免疫原性与治疗效能。两种疫苗均诱导快速、强效且持久的表位特异性抗体反应及Th2偏向免疫应答,并显著延长hSOD1G37R小鼠寿命;tgG-DSE2lim在症状前早期保护更强,tgG-DSE5b显著延迟发病并减缓进展。

要点

  • 两种DSE疫苗均诱导快速强效持久的表位特异性抗体及Th2偏向应答。
  • 两种疫苗均显著延长hSOD1G37R小鼠寿命,tgG-DSE2lim早期保护更优。
  • tgG-DSE5b显著延迟发病并减缓进展,提示构象不同 species 改变表型。

核心结论

  • 基于构象的免疫靶向错误折叠SOD1是减缓甚至阻止SOD1突变相关家族性ALS进展的有前景策略。
  • 该策略也可作为SOD1突变携带者的预防性干预,并可能扩展至TDP-43蛋白病等其他类型ALS。

研究设计与样本

  • 在表达人SOD1-G37R的运动神经元病小鼠模型中评估两种ALS疫苗tgG-DSE2lim和tgG-DSE5b的免疫原性与治疗效能。

主要发现

  • 两种疫苗均诱导快速、强效且持久的表位特异性抗体反应,并呈现理想的Th2偏向免疫应答。
  • 两种疫苗均显著延长hSOD1G37R小鼠的寿命,tgG-DSE2lim在症状前早期阶段显示比tgG-DSE5b更大的保护作用。
  • tgG-DSE5b而非tgG-DSE2lim显著延迟疾病发病并明显减缓疾病进展。

临床怎么用

  • 为开发安全有效的人用抗错误折叠SOD1 ALS治疗性或预防性疫苗提供原理验证数据。
  • 提示基于疾病特异性表位的疫苗策略可扩展至其他类型ALS,如TDP-43蛋白病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emerging evidence suggests seeding and prion-like propagation of mutant Superoxide Dismutase 1 (SOD1) misfolding to be a potential mechanism for ALS pathogenesis and progression. Immuno-targeting of misfolded SOD1 has shown positive clinical outcomes in mutant SOD1 transgenic mice. However, a major challenge in developing active immunotherapies for proteinopathies such as ALS is the design of immunogens enabling exclusive recognition of pathogenic species of a self-protein. Ideally, one would achieve a robust antibody response against the disease-misfolded protein while sparing the natively folded conformer to avoid inducing deleterious autoimmune complications, or inhibiting its normal function. Using a motor neuron disease mouse model expressing human SOD1-G37R, we herein report the immunogenicity and therapeutic efficacy of two ALS vaccines, tgG-DSE2lim and tgG-DSE5b, based on the notion that native SOD1 would undergo early unfolding in disease to present "disease specific epitopes" (DSE). Both vaccines elicited rapid, robust, and well-sustained epitope-specific antibody responses with a desirable Th2-biased immune response. Both vaccines significantly extended the life expectancy of hSOD1G37R mice, with tgG-DSE2lim displaying greater protection than tgG-DSE5b at earlier pre-symptomatic stage. tgG-DSE5b, but not tgG-DSE2lim, significantly delayed disease onset and appreciably slowed disease progression. This implies that conformationally distinct species of misfolded SOD1 may derive from the same mutation, thereby modifying disease phenotypes in a different fashion. Our results validate the rationale for conformation-based immuno-targeting of misfolded SOD1 as a promising therapeutic strategy to slow or even halt disease progression in familial ALS associated with SOD1 mutations, as well as a prophylactic intervention for carriers of SOD1 mutations. Our study not only provides important proof-of-principle data for the development of a safe and effective human therapeutic/prophylactic ALS vaccine against misfolded SOD1, but also predicts a great potential to extend our DSE-based vaccination approach to other types of ALS, such as those associated with TDP-43 proteinopathies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhao B, Marciniuk K, Gibbs E, et al. Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1. Vaccine. 2019. PMID: 31324499. doi:10.1016/j.vaccine.2019.07.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。